{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 133,
  "pageCount": 415,
  "prevPage": 132,
  "nextPage": 134,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide highlights that GH induces insulin resistance while DCCR blocks insulin release, creating a synergistic risk for hyperglycemia.",
  "elementsJson": [
    "paragraph",
    "headline_text",
    "data_table",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/133",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-133",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Both DCCR and GH are independently diabetogenic, and the combination therapy poses a significant and underappreciated metabolic risk in PWS patients.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2a0-1b560d52348b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Growth hormone usage: 84%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2a0-1d301af4c090",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.32,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "The vast majority of PWS patients are on growth hormone as standard of care, as evidenced in Soleno’s Phase 3 double-blind study where 84% of ITT patients (n=104) were on GH, and 82% in the open-label extension. Both DCCR and GH are independently diabetogenic, and the combination therapy poses a significant and underappreciated metabolic risk in PWS patients. GH induces insulin resistance. Under normal conditions, the body compensates via increased insulin secretion. However, diazoxide blocks pancreatic insulin release, eliminating this compensatory mechanism and creating a synergistic driver toward hyperglycemia and type 2 diabetes.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e273edf9-6c6f-416b-b9c9-e05f68730378",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.5,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC10271219/; https://pubmed.ncbi.nlm.nih.gov/37919617/",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e710121-e558-4562-8f02-654c85718e5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.46,
        "x": 0.07,
        "y": 0.73
      },
      "kind": "table",
      "text": "ITT Population (N=125) table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2604b9f7-45d1-48c8-a41a-a0e08aea0f73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.45
      },
      "kind": "table",
      "text": "Table 1. Demographics and baseline characteristics of participants with Prader-Willi syndrome",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b15976c-0789-41b2-9745-03b13163e248",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.07,
        "y": 0.4
      },
      "kind": "title",
      "text": "GH status in phase 3 double-blind study (top) and OLE (below) – table excerpts",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6fc08a34-7483-4b0f-927c-24d755288425",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "4ead0a5b-8580-4f9e-bc13-640091f4b3da",
      "evidence": "The slide explicitly links GH (insulin resistance) + DCCR (blocks insulin release) = synergistic risk for hyperglycemia.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}